XL092-303
A Randomized Open-Label Phase 3 Study of XL092 +Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
COVID-19: We are currently offering vaccinations to current qualifying patients. CURRENT PATIENTS VACCINATION INFO.
A Randomized Open-Label Phase 3 Study of XL092 +Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
Learn more about our Cancer Treatment Team by scrolling below, or visit our Meet the Team page.